EOS imaging to Present at the Canaccord Genuity Musculoskeletal Conference

CAMBRIDGE, Mass. & PARIS--(BUSINESS WIRE)--EOS imaging (NYSE Euronext, FR0011191766 – EOSI), the pioneer in 2D/3D orthopedic medical imaging, announced today that Marie Meynadier, Chief Executive Officer, is scheduled to present at the Canaccord Genuity Musculoskeletal Conference in Chicago, IL.

Event: Canaccord Genuity Musculoskeletal Conference
Date: Tuesday, March 19, 2013
Time: 3:40 p.m. CT / 4:40 p.m. ET

A live webcast of the presentation will be available on EOS imaging’s website at www.eos-imaging.com. A replay of the webcast will be available for 20 days after the date of the presentation.

About EOS imaging:

The EOS imaging group designs, develops and markets EOS®, a revolutionary and patented medical imaging system, based on technology that enabled George Charpak to win the Nobel Prize for Physics. The Group has obtained authorization to market the system in 30 countries, including the United States (FDA), Canada, Australia and the European Union (EU). With an installed base of 60 sites and more than 350,000 imaging sessions, EOS® benefits from worldwide recognition and established credibility within the medical community. The Group currently employs 63 people, including an R&D team of 23 engineers, and recorded consolidated revenue of €9.41 million in 2012. The Group's head office is based in Paris, with a subsidiary in the United States in Cambridge (Massachusetts), as well as in Montreal (Canada) and Germany. For further information, please go to: www.eos-imaging.com.

EOS imaging is listed on Compartment C of the NYSE Euronext Paris
ISIN: FR0011191766 – Ticker: EOSI